WuXi AppTec Co., Ltd. — M&A Activity 2025

Oct 26, 2025

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

WuXi APPTEC CO., LTD.*

無錫藥明康德新藥開發股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2359)

BUSINESS UPDATE IN CONNECTION WITH DISPOSAL OF SUBSIDIARIES

On October 24, 2025, WuXi AppTec (Shanghai) Co., Ltd. ("WXAT Shanghai"), being a wholly-owned subsidiary of the Company), and Hillhouse Investment Management ("Hillhouse") entered into a sale and purchase agreement (the "SPA"), pursuant to which WXAT Shanghai agreed to sell, Hillhouse agreed to purchase, all of the shares in WuXi Clinical Development Services (Shanghai) Co., Ltd. ("WuXi Clinical") and WuXi MedKey Med-Tech Development (Shanghai) Co., Ltd. ("WuXi MedKey"), for cash consideration (the "Transaction"). Hillhouse is one of the world's leading global private asset managers focusing on sectors such as healthcare, manufacturing, green energy, hard technology, and consumer technology.

The management of the Company is of the view that the Transaction reflects the Company's long-term strategy to continuously focus on its core CRDMO business model, emphasizing drug discovery, laboratory testing, process development and manufacturing services. This move is expected to provide financial support and accelerate the development of global capabilities and capacities to better serve customers for the benefit of patients worldwide.

WuXi Clinical and WuXi MedKey are operating entities of the Company engaged in China-based clinical research services business. From January 2025 to September 2025, the aggregate revenue generated by WuXi Clinical and WuXi MedKey was approximately RMB1.16 billion (unaudited), accounting for approximately $3.5\%$ of the Company's unaudited revenue from the first three quarters of 2025. From January 2025 to September 2025, the aggregate net profit generated by WuXi Clinical and WuXi MedKey was approximately RMB0.09 billion (unaudited), accounting for approximately $0.7\%$ of the Company's unaudited net profit from the first three quarters of 2025. Hillhouse is not a connected person of the Company under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Hong Kong Listing Rules").

---

The Transaction on an aggregated basis does not constitute a connected transaction or a notifiable transaction of the Company under Chapter 14A and Chapter 14 of the Hong Kong Listing Rules, respectively. Further, the Transaction does not constitute a major transaction of the Company under the Rules Governing the Listing of Stocks on Shanghai Stock Exchange, a related parties transaction, or a material asset restructuring as stipulated under the Measures for the Administration of the Material Asset Restructurings of Listed Companies. The Transaction is subject to completion in accordance with the agreements under the SPA, including the satisfaction of conditions precedent and obtaining of necessary regulatory approvals. The Company will make further announcement(s) after completion as and when appropriate.

This announcement is made by the Company to keep the shareholders and potential investors of the Company informed of the business update of the Group.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
WuXi AppTec Co., Ltd.*
Dr. Ge Li
Chairman

Hong Kong, October 24, 2025

As of the date of this announcement, the Board of the Company comprises Dr. Ge Li, Dr. Minzhang Chen, Dr. Steve Qing Yang and Mr. Zhaohui Zhang as executive Directors, Mr. Xiaomeng Tong and Dr. Yibing Wu as non-executive Directors and Ms. Christine Shaohua Lu-Wong, Dr. Wei Yu, Dr. Xin Zhang, Ms. Zhiling Zhan and Mr. Xuesong Leng as independent non-executive Directors.

• For identification purposes only